Intellectual Property

  • March 05, 2025

    Rival Cos. Called 'Empower' Agree To End TM Fight, For Now

    Empower Annuity Insurance Co. of America and Empower Finance Inc. agreed to end, for now, their trademark infringement dispute over the "Empower" mark, over a year after a Colorado federal judge found customer confusion was "unlikely" in the financial services sector and refused to order Empower Finance to change its name.

  • March 05, 2025

    PTAB Bar Urges Congress, Lutnick To Protect USPTO Workers

    The PTAB Bar Association is calling on intellectual property leaders in Congress, along with Commerce Secretary Howard Lutnick, to spare the U.S. Patent and Trademark Office from Trump administration initiatives to freeze hiring and require in-person work.

  • March 05, 2025

    Fed. Circ. Backs PNC's PTAB Win Over Mobile Banking IP

    The Federal Circuit on Wednesday affirmed a win PNC Bank landed at an administrative patent board against a Texas bank that is suing PNC over mobile banking technology.

  • March 05, 2025

    Celltrion Can't Undo Eye Med Biosimilar Injunction On Appeal

    The Federal Circuit on Wednesday affirmed a lower court's preliminary injunction barring South Korea-based Celltrion Inc. from launching a biosimilar version of Regeneron's blockbuster eye disease treatment Eylea, rejecting Celltrion's argument that it has shown a patent on the drug may be invalid.

  • March 05, 2025

    Justices Asked To Recuse Fitbit Judge Over Google Ties

    A Silicon Valley-based patent-holding company that lost its infringement case against Fitbit is telling the U.S. Supreme Court that a California federal judge and her husband's financial ties to Fitbit parent Google are so strong that "if these circumstances do not warrant recusal ... then nothing does."

  • March 05, 2025

    Teva Wants Pause Of Patent Delisting For High Court Appeal

    Israeli drugmaker Teva Pharmaceuticals is hoping the Federal Circuit will keep an injunction ordering it to remove its inhaler patents from the U.S. Food and Drug Administration's Orange Book on hold while it appeals the matter to the U.S. Supreme Court.

  • March 05, 2025

    Disney Doesn't Allow IP Theft, 'Moana' Co-Creator Testifies

    One of the creators of "Moana" testified in a California federal copyright trial Wednesday that he "would never" use another writer's idea without permission, noting that one of his projects was killed after The Walt Disney Co. was unable to buy source material.

  • March 05, 2025

    Bezos' Satellite Co. Drops Docs Fight With His Newspaper

    Jeff Bezos' satellite company has ended a public records fight with the Bezos-owned Washington Post over Washington state labor department workplace investigation records, after both sides agreed on blacking out some details to shield trade secrets.

  • March 05, 2025

    NJ Panel Wrestles With Reviving Lorillard's Tax Refund Claim

    New Jersey state appeals court judges grappled Wednesday with whether to revive tax refund claims from Lorillard following a state Tax Court decision that said changes to a royalty addback and deduction rule retroactively fixed constitutional issues with the regulation.

  • March 05, 2025

    Fed. Circ. Says Marketing Costs Can Permit ITC Patent Suits

    The Federal Circuit ruled Wednesday that the U.S. International Trade Commission has wrongly prohibited domestic expenses related to sales, marketing and other activities from allowing companies to pursue ITC patent cases, and revived a suit brought by eyelash extension company Lashify.

  • March 05, 2025

    Parameters Set For Final NIL Deal Approval Hearing

    The California federal judge overseeing the massive $2.78 billion name, image and likeness settlement between the National Collegiate Athletic Association and former and current student-athletes has released guidelines for the deal's final approval hearing in April.

  • March 05, 2025

    Steven Madden Resolves Libel Dispute Over IP Allegations

    Parties in Steven Madden Ltd.'s lawsuit accusing Danish "affordable luxury" brand Ganni A/S of falsely claiming that two of its shoe designs infringed Ganni's intellectual property have reached an agreement to resolve the dispute, according to a filing Tuesday in New York federal court.

  • March 05, 2025

    Fed. Circ. Keeps Lenovo, Databricks Patent Fights In Texas

    The Federal Circuit has turned down efforts by Lenovo and Databricks to ship separate lawsuits they are facing from patent-holding companies out of the Eastern District of Texas.

  • March 05, 2025

    HBO Wins Initial Toss Of 'Chernobyl' IP Case

    A New York federal judge has dismissed a Ukrainian videographer's lawsuit accusing HBO and Sky UK of ripping off his video readout of a firefighter's call for its historical miniseries "Chernobyl," allowing him to file an amended complaint only for the copyright infringement claims.

  • March 05, 2025

    Broadcom Slams 'Meritless Retaliatory' Netflix Patent Suit

    Technology giant Broadcom blasted a patent infringement lawsuit filed by Netflix over five software patents Broadcom contends are invalid and urged a federal California court to toss the litigation, calling it a "meritless retaliatory case" meant to distract from Netflix's "rampant infringement of patents owned by Broadcom-related entities."

  • March 05, 2025

    Paul Newman's Daughters End IP Suit Against Newman's Own

    Late actor Paul Newman's daughters withdrew their lawsuit from Connecticut state court accusing the Newman's Own Foundation of trading off their father's name for non-food-related purposes and breaching its duty to fund their own foundations despite the deceased film star's intent.

  • March 05, 2025

    Alibaba Denies Control Over Copycat Dr. Martens Adverts

    E-commerce site Alibaba has told a London court that it played no part in creating sponsored online advertising containing trademarks owned by Dr. Martens, but claims that the iconic leather boot brand also has not genuinely used all its trademarks.

  • March 05, 2025

    Pfizer, BioNTech Get PTAB To Invalidate Moderna Vaccine IP

    The Patent Trial and Appeal Board handed a massive victory to Pfizer and BioNTech on Wednesday, as it invalidated two Moderna patents covering its Spikevax COVID-19 vaccine, which the challengers stand accused of infringing.

  • March 05, 2025

    Court Finds StockX Liable In Counterfeit Nike Sneaker Suit

    Following oral arguments in New York federal court on Tuesday, a judge found sneaker reseller StockX LLC liable for selling counterfeit Nike shoes, ordering the companies to find available trial dates this year for the remaining allegations.

  • March 04, 2025

    Agencies Have 'Ultimate' Authority Over Firings, OPM Says

    The Office of Personnel Management on Tuesday issued a revised version of its January memo directing agency heads to identify all probationary employees, adding a disclaimer that OPM "is not directing agencies to take any specific performance-based actions" and that agencies "have ultimate decision-making authority."

  • March 04, 2025

    Car Cos. Need Facts, Not Opinions, In Patent Suit, Judge Says

    A Michigan federal judge on Tuesday pressed auto manufacturers for concrete proof that Neo Wireless investors withheld key information about a rival's project from patent officials, telling the carmakers they can't just fall back on an out-of-state judge's opinion to win the patent dispute.

  • March 04, 2025

    ITC To Weigh Essential Patent Import Bans In Amazon Row

    The U.S. International Trade Commission is seeking public comments on whether the owners of standard-essential patents should be able to obtain ITC import bans on infringing products, in a case where a judge found that Amazon TVs and tablets infringed Nokia video patents.

  • March 04, 2025

    PTAB Orders Mostly Backing Apple, Others Upheld On Appeal

    The Federal Circuit on Tuesday affirmed Patent Trial and Appeal Board decisions that Apple and others had shown most claims of a patent on using cameras to sense gestures by users are invalid, but said the board correctly upheld two claims.

  • March 04, 2025

    Phillips 66 'Trickery' Merits $1.2B More Damages, Judge Told

    A startup that won a $605 million trade secrets verdict against oil giant Phillips 66 argued Tuesday in California state court that its would-have-been acquirer owes an additional $1.2 billion for reprehensible conduct, including by in-house counsel who supposedly made "efforts to cover up" information theft.

  • March 04, 2025

    Apple Seeks Ban Against Masimo's Original Smartwatch

    Apple has urged a Delaware federal judge to issue an injunction against a healthcare technology company found last year to have infringed two of the tech giant's design patents with its W1 smartwatch and charger, calling the defense's refusal to agree to the injunction "telling."

Expert Analysis

  • Trump, Tariffs And Tech: The Right To Repair In 2025

    Author Photo

    The "right-to-repair" movement has helped make it easier for independent repair shops and consumers to repair their devices and vehicles — but President-elect Donald Trump's complicated relationship with Big Tech, and his advocacy for increased tariffs, make the immediate future of the movement uncertain, say attorneys at Carter Ledyard.

  • E-Discovery Quarterly: Rulings On Custodian Selection

    Author Photo

    Several recent rulings make clear that the proportionality of additional proposed custodians will depend on whether the custodians have unique relevant documents, and producing parties should consider whether information already in the record will show that they have relevant documents that otherwise might not be produced, say attorneys at Sidley.

  • Fed. Circ. Patent Decisions In 2024: An Empirical Review

    Author Photo

    Despite an ever-increasing backlog of argument-ready cases, the Federal Circuit issued fewer decisions in 2024 than in previous years, and the decisions' overall friendliness toward patent owners and applicants was low, says Dan Bagatell at Perkins Coie.

  • What To Expect In Higher Ed Enforcement Under Trump

    Author Photo

    Colleges and universities should prepare for shifting priorities, as President-elect Donald Trump is likely to focus less on antitrust cases and more on foreign relations policy, while congressional oversight of higher education continues to increase, say attorneys at Steptoe.

  • How Trial Attys Can Wield Amended Federal Evidence Rules

    Author Photo

    Trial lawyers should assess recent amendments to four Federal Rules of Evidence and a newly enacted rule on illustrative aids to determine how to best use the rules to enhance pretrial discovery and trial strategy, says Stewart Edelstein, former litigation chair at Cohen & Wolf.

  • Series

    Exercising On My Peloton Bike Makes Me A Better Lawyer

    Author Photo

    While I originally came to the Peloton bike for exercise, one cycling instructor’s teachings have come to serve as a road map for practicing law thoughtfully and mindfully, which has opened opportunities for growth and change in my career, says Andrea Kirshenbaum at Littler.

  • 5 Drug And Device Developments That Shaped 2024

    Author Photo

    The last year saw significant legal developments affecting drug and device manufacturers, with landmark decisions and regulatory changes that require vigilance and agility from the industry, say attorneys at Faegre Drinker.

  • Rejoinder Strategy After Allergan Double-Patenting Case

    Author Photo

    A closer look at last year's Allergan v. MSN case at the Federal Circuit highlights the importance of rejoinder during patent prosecution in view of the risks associated with obviousness-type double patenting based on later-filed applications in the same patent family, say attorneys at BCLP.

  • 7 Pitfalls To Watch In Tech Referral Fee Programs

    Author Photo

    The recent attempt by FluidStack to recover $10 million in referral fees allegedly promised by software vendor Denvr Dataworks should alert potential participants in so-called partnership programs to seven signs that a proposed technology referral agreement may not equally benefit all sides, says Chris Wlach at Huge Inc.

  • Takeaways From 2024's Emerging IP Licensing Trends

    Author Photo

    Themes in intellectual property licensing from the past year – including artificial intelligence; risk management; and name, image and likeness rights – highlight key considerations for navigating an evolving landscape, say attorneys at Ballard Spahr.

  • Top 10 Legal Issues This Year For Transportation Industry GCs

    Author Photo

    General counsel must carefully consider numerous legal and policy challenges facing the automotive and transportation industry in the year to come, especially while navigating new technologies, regulations and global markets, says Francesco Liberatore at Squire Patton.

  • Exploring Venue Strategy For Trump-Era Regulatory Litigation

    Author Photo

    Litigation will likely play a prominent role in shaping policy outcomes during the second Trump administration, and stakeholders have several tools at their disposal to steer regulatory litigation toward more favorable venues, say attorneys at Covington.

  • How The UPC, ITC Complement Each Other In Patent Law

    Author Photo

    Attorneys at Ropes & Gray discuss the similarities and differences between the Unified Patent Court and the International Trade Commission, as well as recent matters litigated in both venues and why parties choose to file at these forums.

  • Series

    Playing Esports Makes Me A Better Lawyer

    Author Photo

    Competing in a global esports tournament at Wimbledon last year not only fulfilled my childhood dream, but also sharpened skills that are essential to my day job, including strategic thinking, confidence and networking, says AJ Schuyler at Jackson Lewis.

  • Identifying Deepfakes During Evidence Collection, Discovery

    Excerpt from Practical Guidance
    Author Photo

    Attorneys must familiarize themselves with the tools used to create and detect deepfakes — media manipulated by artificial intelligence to convincingly mimic real people and events — as well as best practices for keeping this fabricated evidence out of court, says Bijan Ghom at Saxton & Stump.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Intellectual Property archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!